Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Stocks to Watch today: HDFC Bank, Biocon, SJVN, Container Corp, Yes Bank
Stocks to Watch today, June 30, 2026: Tech Mahindra, Axis Bank, Godrej Properties, RITES, SIS, Jagsonpal Pharma, and Sterling and Wilson Renewable Energy are top stocks to remain in focus
Laurus Labs, Biocon, Ather Energy, Lenskart among probable MSCI India Standard Index inclusion candidates, says JM Financial
JM Financial anticipates significant shifts in the MSCI India Standard Index. Laurus Labs and Biocon are flagged as high-probability additions from the Small Cap Index, while Ather Energy and SAIL are medium-probability candidates. SBI Card faces a high probability of exclusion. These potential changes could lead to substantial passive fund inflows into India, estimated around $3.2 billion, impacting institutional investors.
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for Biocon
Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalizing on growing demand as major pharmaceutical companies shift focus to newer weight-loss drugs. Currently the third-largest global insulin provider, Biocon is significantly expanding production. This strategic move addresses a critical gap in the market, particularly in emerging economies.
Biocon shifts focus to margins, capacity utilisation after expansion phase
Biocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in global capabilities. The company reported a 13% revenue increase for FY26, though net profit saw a substantial decline. Biocon is also prioritizing sustainable, profitable growth and exploring in-licensing opportunities for its biosimilars portfolio.
Promoter Shareholding: Godrej Properties, Adani Energy see stake hike; BHEL, Vishal Mega Mart, Biocon face cuts
Promoter Shareholding: The companies that recorded an increase in promoter ownership between the December 2025 and March 2026, Godrej Properties saw promoter holding rise from 47.2% to 51.7%, while Adani Energy Solutions witnessed an increase from 71.2% to 72.7%.
Q4 Results Today: BSE, Dabur, Britannia, Biocon, MGL Among Over 100 Firms To Declare Earnings On May 7
Indraprastha Gas, Bharat Forge, ACME Solar Holdings, Karur Vysya Bank and CarTrade Tech are among the key firms that will declare quarterly results today.
Q4 Results LIVE Updates: Bajaj Auto reacts to earnings beat, buyback; Lupin, Biocon report today
Q4 Results LIVE Updates: Bajaj Auto reacts to results, along with platform stocks Meesho, Paytm and PB Fintech. Britannia, Lupin, Biocon, Bharat Forge among eight F&O names report results today. Watch this space for all the LIVE updates.
Stocks to Watch today: BSE, MRF, L&T, Paytm, Meesho, Biocon, Bajaj Auto
Stocks to Watch today, May 7, 2026: Mahindra Lifespaces, Deepak Fertilizers, Newgen Software, and Pidilite Industries are among the top stocks to watch today
The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garage
Kiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who built the company from a garage into a global biotech leader, Kiran is ensuring continuity by handing over to a science-driven leader while remaining at the helm during the transition.
Biocon shares rise 1% after billionaire Kiran Mazumdar-Shaw names niece as successor
Biocon's chairperson, Kiran Mazumdar-Shaw, has named her niece, Claire Mazumdar, as her successor, sparking a more than 1% jump in the company's shares. Shaw, who founded Biocon over 40 years ago, expressed confidence in Claire's ability to lead the company's future growth, driven by advanced biotech and AI.
Claire Mazumdar: A silent force behind a $1.6 billion firm may write Biocon's future scripts
Biocon founder Kiran Mazumdar-Shaw has named her niece, Claire Mazumdar, as her successor. Claire Mazumdar, a successful CEO of Bicara Therapeutics, brings scientific expertise and deal-making skills. She is poised to lead Biocon into its next growth phase. The company is focusing on biosimilars and advanced biologics.
With sights on huge gains, Biocon to scale up AI focus
Biopharma major Biocon is significantly scaling up its adoption of artificial intelligence across its operations, from R&D to manufacturing and procurement. This strategic investment aims to achieve substantial cost savings, accelerate drug development timelines, and enhance its competitive edge in the global market.